BioMotiv aims to advance a portfolio of discoveries into new medicines through an innovative, mission-driven model that efficiently aligns capital and collaborations for the benefit of inventors and investors, and ultimately physicians and patient


BioAtla is a global biotechnology company focused on the development of Conditionally Active Biologics (CAB) antibody therapeutics. BioAtla's patents protected CAB platform represents a disruptive technology for the development of a powerful new class of immunotherapeutics that are activated in selected microenvironments within the body such as those indicative of cancerous tumors. With operations in San Diego, California and Beijing, China, and with over 100 patents issued and pending that cover its platform technologies, BioAtla possesses a full complement of therapeutic protein development capabilities.